In fact, CBX3 KO makes IFNγ-insensitive CRC cells become radically sensitive to IFNγ, this modification considerably improves the efficacy of the two oldest and widely used CRC chemotherapy drugs: Irinotecan and 5-FU. This evidence concerns the gene IFNG and colorectal carcinoma.